FDA Grants Accelerated Approval to Zongertinib for Non-squamous NSCLC with HER2 Tyrosine Kinase Domain Activating Mutations By Ogkologos - August 29, 2025 683 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the Beamion LUNG-1 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR NBC’s Kristen Dahlgren Discusses The Unexpected Breast Cancer Symptom She Almost... December 13, 2019 Texting May Help Reduce Disparities in Colorectal Cancer Screening March 19, 2021 Blinatumomab Boosts Chemotherapy as Initial Treatment for Some Kids with ALL February 13, 2025 FDA Approves Olutasidenib for Relapsed or Refractory Acute Myeloid Leukaemia with... December 9, 2022 Load more HOT NEWS Biomarker Data from the KAITLIN Study in High-Risk Early Breast Cancer More Evidence that One HPV Vaccine Dose Protects against Cancer-Causing Infections A Cancer Revolution comes to Manchester: Patrick’s review 2023 ASCO Annual Meeting Research Round Up: Progress in Preventing Melanoma...
